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Introduction: The vascular and nervous systems have several anatomic and molecular mechanism similarities.
Emerging evidence suggests that proteins involved in transmitting axonal guidance cues, including members of
class III semaphorin (Sema3) family, play a critical role in blood vessel guidance during physiological and
pathological vascular development. Sema3E is a natural antiangiogenic molecule that causes filopodial retraction in
endothelial cells, inhibiting cell adhesion by disrupting integrin-mediated adhesive structures. The aim of the
present study was to investigate whether in systemic sclerosis (SSc) Plexin-D1/Sema3E axis could be involved in the
dysregulation of vascular tone control and angiogenesis.
Methods: Sema3E levels were measured by quantitative colorimetric sandwich ELISA in serum samples from 48 SSc
patients, 45 subjects with primary Raynaud's phenomenon (pRP) and 48 age-matched and sex-matched healthy
controls. Immunofluorescence staining on skin sections from 14 SSc patients and 12 healthy subjects was performed to
evaluate Sema3E and Plexin-D1 expression. Western blotting was used to assess Plexin-D1/Sema3E axis in human SSc
and healthy dermal microvascular endothelial cells (SSc-MVECs and H-MVECs, respectively) at basal condition and after
stimulation with recombinant human vascular endothelial growth factor (VEGF), SSc and healthy sera. Capillary
morphogenesis on Matrigel was performed on H-MVECs treated with healthy, pRP or SSc sera in the presence of
Sema3E and Plexin-D1 soluble peptides.
Results: Serum Sema3E levels were significantly higher both in pRP subjects and SSc patients than in controls. In SSc,
Sema3E levels were significantly increased in patients with early nailfold videocapillaroscopy (NVC) pattern compared
to active/late patterns and pRP, and in patients without digital ulcers versus those with ulcers. In SSc skin, Sema3E
expression was strongly increased in the microvascular endothelium. Cultured SSc-MVECs showed higher levels of
phosphorylated Plexin-D1 and Sema3E expression than H-MVECs, and stimulation with SSc sera increased
phosphorylated Plexin-D1 and Sema3E in H-MVECs. The addition of Sema3E-binding Plexin-D1 soluble peptide
significantly attenuated the antiangiogenic effect of SSc sera on H-MVECs.
Conclusions: Our findings suggest that Plexin-D1/Sema3E axis is triggered in SSc endothelium and may have a role in
the dysregulation of angiogenesis and vascular tone control by inducing neuro-vascular mechanism alterations
clinically evident in particular in the early disease phases.* Correspondence: celestina.mazzotta@unifi.it
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Systemic sclerosis (SSc) is a multisystem autoimmune dis-
ease of unknown etiology characterized by vascular dam-
age, activation of the immune system, and excessive
deposition of collagen in the skin and internal organs in-
cluding lungs, heart, gastrointestinal tract, and kidneys [1].
SSc is classified into limited cutaneous (lcSSc) and diffuse
cutaneous (dcSSc) subsets and, in both, is associated with
Raynaud's phenomenon (RP), nailfold capillaroscopic
changes and antinuclear antibody positivity [2]. RP is char-
acterized by recurrent, reversible episodes of vasospasm
involving peripheral small vessels [3–5]. Early in the patho-
genesis of RP, endothelial dysfunction increases platelet
adhesion and favours dysfunctional control of vascular
tone [6]. Endothelial cells are intimately involved in the
regulation of vascular tone by synthesis and release of neu-
rotransmitters, cytokines, growth factors, and prostaglan-
dins, which mediate vasodilation and vasoconstriction [7].
Moreover, the vascular wall consists of endothelial, smooth
muscle and fibroblast cells working in an integrated system
of cellular paracrine/autocrine regulation interacting with
the peripheral nervous system. The pathophysiology of RP
is still not completely understood, but it has been sug-
gested that dysregulation in neuro-endothelial control
mechanisms plays a key role in RP pathogenesis [8].
Indeed, the vascular and nervous systems have several
anatomical similarities that extend to molecular level, and
the molecular mechanisms of nerve regulation are shared
by the vascular system [9–12]. In some cases, vessels pro-
duce signals that attract axons to track alongside the pion-
eer vessels, conversely, nerves may also produce signals
such as vascular endothelial growth factor (VEGF) to
guide blood vessel growth. During embryogenesis, the
developing nervous and vascular systems follow parallel
routes and share several molecular pathways, including
netrins, ephrins, and semaphorins, which act as both axon
guidance molecules and regulators of developmental and
postnatal angiogenesis [9, 13]. Among them, secreted class
III semaphorins (Sema3s) control endothelial cell migra-
tion in vitro and in vivo [14, 15]. Semaphorins are grouped
into eight classes based on their structural domains, and
they are characterized by an amino-terminal Sema domain
that is essential for signaling and can play a repulsive or
attractive role depending on the cell types and biological
context [16–18]. All Sema3 proteins (except Sema3E) sig-
nal through two major receptor families, namely Plexins
and Neuropilins (NRPs), by forming a holoreceptor com-
plex consisting of NRPs as ligand binding, and Plexins as
signal transducing subunit. Conversely, Sema3E is unique
in that it binds and signals directly through Plexin-D1
(PlxnD1), independently of NRPs. Plexins are single-pass
transmembrane receptors subdivided into four groups,
namely type A, B, C and D Plexins, with an extracellular
Sema domain. Semaphorins target the actin cytoskeletonand focal adhesions, inducing cytoskeletal remodeling, cell
motility, and cell migration [19, 20]. Furthermore, it has
been shown that Sema3E acts on PlxnD1 in endothelial
cells to start an antiangiogenic signaling pathway [21],
through the disassembly of integrin-mediated focal adhe-
sions and consequent inhibition of endothelial cell adhe-
sion to the extracellular matrix, ultimately leading to
filopodia retraction in endothelial cells of growing blood
vessels (Fig. 1) [22]. Moreover, PlxnD1 was shown to be
highly expressed in angiogenic endothelial cells, and it was
found to regulate the morphogenic patterning of develop-
ing vascular networks [13].
On these premises, the aims of this study were to inves-
tigate 1) the possible contribution of the antiangiogenic
PlxnD1/Sema3E pathway in angiogenesis disturbances
and development of capillary abnormalities and digital ul-
cers (DUs) during SSc [23–26], and 2) if this axis might
participate in the dysregulation of vascular tone control in
both SSc and primary RP (pRP).
Methods
Study participants
Serum samples were obtained from 48 patients with SSc
(43 female and 5 male patients; median age 64 years,
range 37 to 78 years), defined as limited cutaneous SSc
(lcSSc; n = 36) or diffuse cutaneous SSc (dcSSc; n = 12)
[27], 45 subjects with pRP and 48 age-matched and sex-
matched healthy controls. All SSc patients reported the
occurrence of RP. Nailfold videocapillaroscopy (NVC)
was performed on 10 fingers and all SSc patients were
classified as having early, active and late NVC patterns
[28]. At the time of blood collection, the presence of DUs
was recorded. DUs related to trauma or calcinosis were
not included in the analyses. The patients enrolled were
not on corticosteroids, immunosuppressants or other
disease-modifying drugs or calcium channel blockers.
Peripheral blood samples were collected without any addi-
tive, left to clot for 30 minutes before centrifugation at
1,500 g for 15 minutes, and serum was collected and
stored in aliquots at −80 °C until used. Paraffin-embedded
sections of lesional forearm skin biopsies were obtained
from 14 patients with SSc (12 women and 2 men, n = 9
with lcSSc and n = 5 with dcSSc; median age 46.8 years,
range 27 to 69 years, and median disease duration 6 years,
range 1 to 16 years) and 12 age-matched and sex-matched
healthy donors. The study was approved by the Ethical
Committee of the Azienda Ospedaliero-Universitaria
Careggi (AOUC), Florence, Italy, and all subjects provided
written informed consent.
Isolation of dermal microvascular endothelial cells
(MVECs) and cell culture
Human dermal MVECs were isolated from skin biopsies of
five SSc patients (SSc-MVECs) and five healthy subjects
Fig. 1 Schematic representation of Plexin-D1/Semaphorin 3E (Sema3E) axis in endothelial cells. Binding of Sema3E to the cell surface receptor
Plexin-D1 activates an antiangiogenic signaling pathway leading to the disassembly of integrin-mediated focal adhesions, inhibition of endothelial
cell adhesion to the extracellular matrix, and filopodia retraction in endothelial cells of growing blood vessels
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to remove the adipose and epidermis layers, in order to ob-
tain a pure specimen of vascularized dermis, and were
treated as previously described [29]. The samples were
placed at 37 °C in a humidified atmosphere with 5 % CO2.
After one day of culture in endothelial cell basal medium
(EBM-2, catalog number LOCC3156; Euroclone, Milan,
Italy) supplemented with 20 % fetal bovine serum (FBS),
5 ng/ml H-epidermal growth factor (hEGF; Clonetics Cor-
poration, San Diego, California, USA), 1 μg/ml hydrocorti-
sone acetate, 100 U/ml penicillin, 100 μg/ml streptomycin,
and 25 μg/ml amphotericin B without addition of further
angiogenic growth factors, small colonies of polygonal ele-
ments were detected. Non-adherent cells were removed
and fresh endothelial cell complete medium was added. To
maintain optimal culture conditions, media were changed
every third day, and after 2 weeks of primary culture a
monolayer of cells was obtained. MVECs from primary cul-
tures were further identified using immunomagnetic beads
recognizing CD31. Isolated cells were purified as MVECs
by labeling with anti-factor VIII-related antigen and anti-
CD105, followed by reprobing with anti-CD31 antibodies.
Dermal MVECs were maintained in endothelial cell
complete medium and were used between the third and
seventh passages in culture.
ELISA on serum samples
Serum levels of Sema3E protein were measured by a col-
orimetric sandwich enzyme-linked immunosorbent assay
(ELISA kit, catalogue number ABIN1117868; Antibodies
Online, Aachen, Germany), according to the manufac-
turer’s instructions. Briefly, standards and samples (100
μl/well) were added to the appropriate 96-well microtiterplate pre-coated with a biotin-conjugated polyclonal
antibody specific for the short basic Sema3E domain,
and were incubated for 2 hours at 37 °C. Subsequently
the samples and standard were removed and 100 μl of
Detection Reagent A working solution were added to
each well for 1 hour at 37 °C. The microplates were
washed three times with wash solution, followed by the
addition of 100 μl of Detection Reagent B working solu-
tion (Avidin-conjugated Horseradish Peroxidase (HRP))
to each well, and incubation for 30 minutes at 37 °C.
The microplates were washed five times and the reaction
was developed in the dark with 90 μl of substrate solu-
tion (tetramethylbenzidine) and then stopped by apply-
ing 50 μl of sulfuric acid (1 M H2SO4). The absorbance
of each well was read using a microplate reader at 450
nm. Serum levels of Sema3E were read from a standard
curve prepared using a lyophilized protein standard
reconstituted with standard diluent included in the kit.
The detection range of the assay was 0.156−20 ng/ml.
Each sample was measured in duplicate. Serum Sema3E
concentration was determined by comparing the optical
density (OD) of each sample to the standard curve.
Immunohistochemistry and fluorescence microscopy
Paraffin-embedded skin sections (5 μm thick) were depar-
affinized and boiled for 10 minutes in sodium citrate
buffer (10 mM, pH 6.0) in order to expose antigens. After
three washes in phosphate-buffered saline (PBS), the sec-
tions were incubated in 2 mg/ml glycine for 10 minutes to
quench autofluorescence due to free aldehydes, and then
blocked for 1 hour at room temperature with 1 % bovine
serum albumin (BSA) in PBS. The samples were then in-
cubated overnight at 4 °C with goat anti human Sema3E
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UK) diluted 1:100 in PBS with 1 % BSA. After extensive
washing in PBS, the sections were incubated with Alexa
Fluor-488-conjugated donkey anti-goat IgG for 45 mi-
nutes at room temperature in the dark (1:200 dilution;
Invitrogen, San Diego, CA, USA). For double immuno-
fluorescence staining, we used a rabbit polyclonal antibody
against CD31/platelet-endothelial cell adhesion molecule-
1 (PECAM-1) diluted 1:50 (catalog number ab28364;
Abcam), followed by Alexa Fluor-568-conjugated donkey
anti-rabbit IgG (1:200 dilution; Invitrogen). To evaluate
PlxnD1 expression, skin sections were incubated over-
night at 4 °C with rabbit polyclonal antibody against
human PlxnD1 (catalog number ab28762; Abcam) diluted
1:50 in PBS with 1 % BSA. After extensive washing in
PBS, the section were processed as described above, and
subsequently incubated with Alexa Fluor-488-conjugated
goat anti-rabbit IgG (1:200 dilution; Invitrogen) for 45 mi-
nutes at room temperature in the dark. For double im-
munofluorescence staining with anti-PlxnD1 antibody, we
used a mouse monoclonal anti-CD31 antibody (1:20 dilu-
tion; catalog number M0823; Dako, Glostrup, Denmark)
followed by Rhodamine Red-X-conjugated goat anti-
mouse IgG (1:200 dilution; Invitrogen). Irrelevant isotype-
matched and concentration-matched goat, mouse, and
rabbit IgG (Sigma-Aldrich, St Louis, MO, USA) were used
as negative controls. Nuclei were counterstained with
4′,6-diamidino-2-phenylindole (DAPI) (Chemicon Inter-
national, Temecula, CA, USA). The immunolabeled sec-
tions were then observed under a Leica DM4000 B
microscope equipped with fully automated fluorescence
axes (Leica Microsystems, Mannheim, Germany). Fluores-
cence images were captured using a Leica DFC310 FX
1.4-megapixel digital colour camera equipped with the
Leica software application suite LAS V3.8 (Leica Micro-
systems). Densitometric analysis of the intensity of im-
munofluorescent staining was performed on digitized
images using the free-share ImageJ software (NIH, Be-
thesda, MD, USA; online at [30]).
Western blotting and cell signaling
Total proteins were extracted from dermal H-MVECs
and SSc-MVECs according to standard protocols. In
some experimental conditions, before protein extraction
H-MVECs were cultured for 24 hours in EBM-2 medium
containing 10 % of serum from healthy subjects (n = 5) and
SSc patients (n = 5) or recombinant human VEGF-A165
(10 ng/ml; R&D Systems, Minneapolis, MN, USA). As
determined by ELISA, healthy and SSc serum samples con-
taining Sema3E levels similar to the respective median
group value were used in these experiments. Twenty-five
micrograms of total proteins were electrophoresed on
NuPAGE 4 to 12 % Bis-Tris Gel (Invitrogen) and were blot-
ted on polyvinylidene difluoride membranes (Invitrogen).The membranes were blocked for 40 minutes at room
temperature with the blocking solution included in the
Western Breeze Chromogenic Western Blot Immunodetec-
tion Kit (Invitrogen) on a rotary shaker and incubated for 1
hour at room temperature with rabbit polyclonal antihu-
man PlxnD1 (Sema domain 250 kDa, catalog number
PP4401; 1:1000 dilution; ECM Biosciences, Versailles,
Woodford County, KY, USA), rabbit polyclonal antihuman
PlxnD1 (Cytoplasmic domain 250 kDa, catalog number
PP4421; 1:500 dilution; ECM Biosciences), rabbit polyclonal
antihuman PlxnD1 (a.a. 1635–1647 C-ter region 250 kDa,
catalog number PP4441; 1:500 dilution; ECM Biosciences),
rabbit polyclonal antihuman Sema3E (N-terminal region 87
kDa, catalog number SP4461; 1:1000 dilution; ECM Biosci-
ences) and rabbit polyclonal anti-α-tubulin (catalog number
ab18251; 1:1000 dilution; Abcam) antibodies, assuming α-
tubulin as control invariant protein. Immunodetection was
performed as described in the Western Breeze Chromo-
genic Immunodetection protocol (Invitrogen). ImageJ soft-
ware (NIH) was used for densitometric analysis of the
bands and all values were normalized to α-tubulin.
In vitro capillary morphogenesis assay
In vitro capillary morphogenesis assay was performed in 96-
well plates covered with Matrigel (BD Biosciences, Milan,
Italy). Matrigel (50 μl; 10–12 mg/ml) was pipetted into
culture wells and polymerized for 30 minutes to 1 hour at
37 °C, as described elsewhere [31]. H-MVECs and SSc-
MVECs (30 × 103 cells/well) were incubated in EBM-2
medium containing 10 % FBS. In some experimental condi-
tions, H-MVECs were incubated in EBM-2 medium with 10
% serum from healthy subjects (n = 5), SSc patients (n = 5)
and pRP subjects (n = 5), alone or in combination with
human Sema3E peptide (100 ng/ml; catalog number
ab39320; Abcam), human PlxnD1 peptide (a.a. 1683–1694)
(100 ng/ml; catalog number ab45701; Abcam) or both. As
determined by ELISA, healthy, pRP and SSc serum samples
containing Sema3E levels similar to the respective median
group value were used in these experiments. Stimulation
with recombinant human VEGF-A165 (10 ng/ml; R&D
Systems) was used as positive control of angiogenesis. Plates
were photographed at 6 and 24 hours. Results were quanti-
fied at 24 hours by measuring the percent field occupancy
of capillary projections, as determined by image analysis. Six
to nine photographic fields from three plates were scanned
for each experimental point.
Statistical analysis
Data are expressed as the mean ± standard deviation (SD)
or median and range. The Student’s t test and nonparamet-
ric Mann–Whitney U test were used where appropriate
for statistical evaluation of the differences between two in-
dependent groups. A p value less than 0.05 was considered
statistically significant.
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Serum levels of Sema3E
Sema3E serum levels were significantly increased both in
pRP subjects (median 0.54 ng/ml, range 0.00−1.96 ng/ml)
and SSc patients (median 0.67 ng/ml, range 0.00−1.71 ng/
ml) compared to controls (median 0.19 ng/ml, range 0.00
−0.94 ng/ml) (both p <0.005) (Fig. 2a). No significant dif-
ferences in circulating Sema3E levels were detected be-
tween pRP and SSc (Fig. 2a). Next, we correlated serum
Sema3E levels with NVC patterns as measure of periph-
eral microvascular involvement. In SSc patients with early
NVC pattern, Sema3E levels were significantly increased
(median 1.17 ng/ml, range 0.65−1.35 ng/ml) compared
with active (median 0.65 ng/ml, range 0.00−1.71 ng/ml)
and late (median 0.55 ng/ml, range 0.00−1.35 ng/ml)
NVC patterns (both p <0.05) (Fig. 2b). Moreover, serum
Sema3E in SSc patients with early NVC pattern was sig-
nificantly higher than in pRP subjects (median 0.54 ng/ml,
range 0.00−1.96 ng/ml) (p <0.05). In addition, Sema3E
levels were significantly increased in SSc patients without
DUs (median 1.03 ng/ml, range 0.00−1.71 ng/ml) com-
pared with patients with DUs (median 0.57 ng/ml, range
0.00−1.20 ng/ml) (p = 0.018) (Fig. 2c).
Expression of Sema3E and PlxnD1 in skin biopsies
The expression of Sema3E and its receptor PlxnD1 in
skin biopsies from SSc patients and healthy controls was
evaluated by immunofluorescence (Figs. 3 and 4). Sema3E
expression was strongly increased in several cellular com-
ponents of SSc dermis, such as fibroblasts and perivascu-
lar cells when compared with healthy controls (Fig. 3a, b).
Moreover, double immunofluorescence staining for Sema
3E and the pan-endothelial cell marker CD31/PECAM-1
revealed that Sema3E expression was significantly upregu-
lated in endothelial cells of SSc dermis compared with
healthy control skin (Fig. 3c
-f ). The densitometric analysis of the intensity of im-
munofluorescent staining demonstrated that Sema3E
expression was significantly increased in the dermis of
SSc patients compared with controls (p <0.001)
(Fig. 3g). Conversely, no significant difference in the ex-
pression of PlxnD1 was observed between healthy skin
and skin from patients with SSc in different dermal cell
types, including endothelial cells (Fig. 4a-g).
PlxnD1/Sema3E cell signaling in dermal MVECs
To assess the role of PlxnD1/Sema3E pathway in the
endothelium, we evaluated cell signaling on H-MVECs
cultured in standard condition and after challenge with
recombinant human VEGF-A165 and sera from healthy
subjects or patients with SSc, and in SSc-MVECs cul-
tured in standard conditions. Western blotting analyses
revealed that SSc-MVECs expressed significant higher
levels of the activated form of PlxnD1 (phosphorylated inC-ter domain, a.a. 1635–1647) than H-MVECs (p <0.001)
(Fig. 5a). In addition, the phosphorylated form of PlxnD1
significantly increased in H-MVECs challenged with sera
from patients with SSc compared with both basal H-
MVECs and H-MVECs cultured with sera from healthy
controls (both p <0.05) (Fig. 5a). To validate these results,
we also specifically evaluated the expression levels of the
N-terminal Sema domain region of PlxnD1, which can be
detected only when this domain is not bound by Sema3E.
As shown in Fig. 5b, the detection levels of this region
were significantly lower in SSc-MVECs than in H-
MVECs, and in H-MVECs challenged with sera from pa-
tients with SSc compared with H-MVECs treated with
sera from healthy controls (both p <0.05). Moreover, con-
sistent with the immunohistochemical results, Sema3E
levels were significantly increased in SSc-MVECs in re-
spect to H-MVECs, and in H-MVECs challenged with
sera from patients with SSc compared with H-MVECs
treated with sera from healthy controls (both p <0.05)
(Fig. 5c). No significant differences in total PlxnD1 expres-
sion were found between the different experimental con-
ditions (Fig. 5d). Finally, the stimulation with recombinant
human VEGF-A165 did not significantly affect the
PlxnD1/Sema3E pathway in H-MVECs (Fig. 5a-d).
Capillary morphogenesis on Matrigel
To investigate the functional influence of the PlxnD1/
Sema3E pathway on dermal MVEC in vitro angiogen-
esis, we performed capillary morphogenesis on Matrigel
matrix. In this assay, MVECs usually produce elongated
processes that eventually form anastomosing cords of
cells mimicking a tubular capillary plexus. Consistent
with previous findings [31], in standard conditions
angiogenesis was strongly impaired in SSc-MVECs
compared with H-MVECs (Fig. 6). H-MVECs stimu-
lated with healthy sera produced an abundant network
of branching cords, while the addition of Sema3E sol-
uble peptide to the sera significantly inhibited angio-
genesis (p <0.05 vs healthy serum only) (Fig. 6).
Furthermore, the angiogenic capacity of H-MVECs co-
incubated with healthy sera and Sema3E-binding
PlxnD1 peptide or Sema3E/PlxnD1 combined peptides
was not different compared to that of cells treated with
healthy sera alone (Fig. 6). Similar results were obtained
when H-MVECs were challenged with sera from pa-
tients with pRP, except that co-incubation with pRP
serum and Sema3E-binding PlxnD1 peptide signifi-
cantly increased angiogenesis compared to treatment
with serum from pRP alone (p <0.05) (Fig. 6). More-
over, capillary morphogenesis was reduced in H-
MVECs challenged with sera from patients with pRP
compared with cells treated with healthy sera, but this
difference was not statistically significant. Conversely,
treatment with sera from patients with SSc strongly
Fig. 2 Serum levels of semaphorin 3E (Sema3E) determined by
colorimetric sandwich enzyme-linked immunosorbent assay (ELISA).
a Serum Sema3E levels in healthy controls, subjects with primary
Raynaud's phenomenon (pRP) and patients with systemic sclerosis
(SSc). b Serum Sema3E levels in SSc patients according to nailfold
videocapillaroscopy (NVC) pattern (early, active and late). c Serum
Sema3E levels in SSc patients according to the absence/presence of
digital ulcers (DUs). Data are shown as dot plots. Each dot represents
a subject. Blue horizontal lines indicate the median value in each group.
In each panel, the red dashed line indicates the detection threshold of
the ELISA. The nonparametric Mann–Whitney U test for independent
samples was used to analyze the serum Sema3E differences between
groups. Values of p <0.05 were considered significant; p values are
indicated in each panel
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(Fig. 6). The addition of Sema3E peptide further im-
paired the angiogenic capacity of H-MVECs challenged
with sera from patients with SSc (p <0.05 vs serum
from patients with SSc only) (Fig. 6). On the contrary,
when H-MVECs were co-incubated with sera from
patients with SSc and Sema3E-binding PlxnD1 soluble
peptide, their angiogenic capacity was significantly
increased compared with cells treated with sera from
patients with SSc alone (p <0.05) (Fig. 6).Discussion
Our data show for the first time that 1) serum levels of
Sema3E are significantly increased both in pRP subjects
and SSc patients with secondary RP, and that 2) the
PlxnD1/Sema3E signaling pathway is triggered in SSc-
MVECs and determines an antiangiogenic response.
Blood vessels provide oxygen and nutrients to every
part of the body, and they are essential for tissue homeo-
stasis and repair. Angiogenesis is a physiological process
where new vessels are formed by sprouting of endothe-
lial cells from pre-existent vessels to create and increase
a complex network [32–35]. Angiogenesis is controlled
by a tight and complex balance between proangiogenic
and antiangiogenic signals, and among them VEGF coor-
dinates the angiogenesis process. Moreover, the endothe-
lium produces a large number of vasodilating factors,
including nitric oxide and prostacyclin [36], and vasocon-
stricting substances, such as endothelin-1, with effects on
vascular remodeling [37]. In this context, increasing
evidence indicates that both pRP and secondary RP in
SSc are characterized by severe disturbances in multiple
mechanisms that regulate vascular tone control [2, 24].
Moreover, an impaired angiogenic response following
tissue ischemia and hypoxia is considered a hallmark
feature of SSc [24].
Of note, it is well-established that the autonomic ner-
vous system contributes to the pathogenesis of both pRP
and secondary RP in SSc, via central and peripheral
Fig. 3 Expression of semaphorin 3E (Sema3E) in skin of healthy controls and patients with systemic sclerosis (SSc). a, b Representative
microphotographs of skin sections from healthy controls (a) (n = 12) and patients with SSc (b) (n = 14) immunostained for Sema3E (green)
and counterstained with 4′,6-diamidino-2-phenylindole (DAPI; blue) for nuclei. c-f Representative microphotographs of skin sections from
healthy controls (c, e) (n = 12) and patients with SSc (d, f) (n = 14) double immunostained for Sema3E (green) and CD31/platelet-endothelial
cell adhesion molecule-1 (PECAM-1) (red) and counterstained with DAPI (blue). Arrows indicate Sema3E expression in dermal microvascular
endothelial cells. Original magnification: × 20 (a, b), × 40 (c, d), × 63 (e, f). Scale bars are indicated in each panel. g Densitometric analysis of
Sema3E immunofluorescent staining in skin biopsies expressed as optical density (OD) in arbitrary units (a.u.). Control skin OD value was set to
100 %; the other results are normalized to this value. Data are mean ± SD. Student’s t test was used for statistical analysis
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systems have several morphological and molecular simi-
larities [9, 19, 35]. In fact, emerging evidence suggeststhat proteins involved in transmitting axonal guidance
cues, such as the multiple members of secreted class III
semaphorin family that regulate developmental axonal
Fig. 4 Expression of Plexin-D1 (PlxnD1) in skin of healthy controls and patients with systemic sclerosis (SSc). a, b Representative microphotographs
of skin sections from healthy controls (a) (n = 12) and SSc patients (b) (n = 14) immunostained for PlxnD1 (green) and counterstained with
4′,6-diamidino-2-phenylindole (DAPI; blue) for nuclei. c-f Representative microphotographs of skin sections from healthy controls (c, e) (n = 12)
and SSc patients (d, f) (n = 14) double immunostained for PlxnD1 (green) and CD31/platelet-endothelial cell adhesion molecule-1 (PECAM-1)
(red) and counterstained with DAPI (blue). Arrows indicate PlxnD1 expression in dermal microvascular endothelial cells. Original magnification:
× 20 (a, b), × 40 (c, d), × 63 (e, f). Scale bars are indicated in each panel. g Densitometric analysis of PlxnD1 immunofluorescent staining in
skin biopsies expressed as optical density (OD) in arbitrary units (a.u.). Control skin OD value was set to 100 %; the other results are normalized
to this value. Data are mean ± SD. Student’s t test was used for statistical analysis
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during physiological and pathological vascular develop-
ment [9, 39, 40]. In particular, soluble Sema3E is apotent inhibitor of angiogenesis that binds to its specific
receptor PlxnD1 with consequent activation of a com-
plex antiangiogenic intracellular signaling cascade [23].
Fig. 5 Differential activation of Plexin-D1 (PlxnD1)/semaphorin 3E (Sema3E) cell signaling pathway in dermal microvascular endothelial cells
(MVECs) from healthy controls (H) and patients with systemic sclerosis (SSc). Protein lysates from H-MVECs at basal condition and after stimulation
with recombinant human vascular endothelial growth factor (VEGF)-A165, sera from healthy controls and patients with SSc (both n = 5), and from
SSc-MVECs at basal condition were assayed with antibodies recognizing (a) the activated form of PlxnD1 (phosphorylated in C-ter domain, a.a.
1635–1647), (b) the N-terminal Sema domain region of PlxnD1, (c) Sema3E N-terminal region, and (d) PlxnD1 C-terminal domain. Representative
immunoblots are shown. The densitometric analysis of the bands normalized to α-tubulin is reported in the histograms. Data are mean ± SD of
optical density (OD) in arbitrary units. Student’s t test was used for statistical analysis; p values are indicated in each panel. Results are
representative of three independent experiments performed with each one of the five H-MVEC and five SSc-MVEC lines
Mazzotta et al. Arthritis Research & Therapy  (2015) 17:221 Page 9 of 12The present study was undertaken to investigate
whether the PlxnD1/Sema3E axis could be involved in
the neurovascular component of SSc pathophysiology.For this purpose, we first analyzed circulating levels of
Sema3E both in pRP subjects and SSc patients, as well
as their possible correlation with measures of vascular
Fig. 6 In vitro angiogenesis assay results. Upper panel: representative images of capillary morphogenesis on Matrigel after 24 hours. Lower panel:
capillary morphogenesis of healthy and systemic sclerosis (SSc) dermal microvascular endothelial cells (H-MVECs and SSc-MVECs, respectively) quantified
as percent field occupancy of capillary projections. Capillary morphogenesis of H-MVECs was evaluated at basal condition and after stimulation with
sera from healthy subjects (n = 5), primary Raynaud's phenomenon (pRP) subjects (n = 5), and SSc patients (n = 5) alone or in combination with
human semaphorin 3E (Sema3E) peptide, human Sema3E-binding Plexin-D1 (PlxnD1) peptide (a.a. 1683–1694), or both. Capillary morphogenesis of
H-MVECs at basal condition was set to 100 %; the other results are normalized to this value. Data are the mean ± SD of three independent experiments
performed in triplicate with each one of the five H-MVEC and five SSc-MVEC lines. Six to nine photographic fields from three plates were scanned for
each experimental point. Student’s t test was used for statistical analysis. §p <0.05 vs basal H-MVECs; #p <0.05 vs healthy serum only; °p <0.05 vs serum
from patients with pRP only; *p <0.05 vs serum from patients with SSc only
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increased serum Sema3E levels both in pRP and SSc
compared with healthy individuals, suggesting that this
molecule might participate in the vascular tone distur-
bances characteristic of both clinical entities. Moreover, it
is interesting to note that in SSc increased circulating levels
of Sema3E specifically correlated with the early NVC pat-
tern and the absence of DUs, as patients with more severe
capillary damage and DUs had Sema3E levels comparable
to those of controls. Thus, it is tempting to speculate that
Sema3E might even serve in the future as a biomarker of
early vascular involvement during SSc. Indeed, currently
there are no reliable serological biomarkers for the early
diagnosis of RP and the neuro-vascular involvement in SSc
patients. However, further follow-up studies will be neces-
sary to ascertain whether circulating Sema3E could be a
useful marker to monitor the evolution of SSc-related per-
ipheral vascular disease. Furthermore, we cannot exclude
the possibility that lower Sema3E levels detected in SSc
with more advanced NVC patterns might be either a cause
or a consequence of the disease, which is characterized by
progressive loss of the peripheral microvessels and nervous
fibers [41], which are the main source of Sema3E.
Consistent with serum findings, the expression of
Sema3E in SSc-affected dermis was strongly increased,
particularly in the microvascular endothelium. Conversely,
no difference in the expression of Sema3E receptor
PlxnD1 was found between skin from patients with SSc
and healthy controls. To further address whether the
PlxnD1/Sema3E pathway could be activated in the endo-
thelium in SSc, we performed cell signaling studies on cul-
tured dermal MVECs. Strikingly, our in vitro experiments
demonstrated that although total PlxnD1 expression was
not different in H-MVECs and SSc-MVECs, these latter
showed a significantly increase in the expression of the ac-
tivated form of PlxnD1 (phosphorylated in C-ter domain).
Moreover, phosphorylated PlxnD1 significantly increased
in H-MVECs after challenge with sera from patients with
SSc. Thus, these data support the hypothesis that PlxnD1/
Sema3E pathway is triggered in the microvascular endo-
thelium in SSc. Finally, functional capillary morphogenesis
experiments revealed that such activation of the PlxnD1/
Sema3E pathway may contribute to defective angiogenesis
in SSc. Indeed, we showed that Sema3E exerts antiangio-
genic effects in vitro. Accordingly, serum from patients
with SSc strongly inhibited angiogenesis of H-MVECs,
while the addition of Sema3E-binding PlxnD1 soluble
peptide to sequester elevated Sema3E present in sera
from patients with SSc significantly improved H-MVEC
angiogenesis.
Conclusions
In conclusion, our findings suggest that the PlxnD1/
Sema3E axis is triggered in the endothelium in SSc, andmay have a role in the dysregulation of angiogenesis and
vascular tone control by inducing neurovascular mech-
anism alterations, which are clinically evident in particu-
lar in the early disease phases.
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